Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Growth in Short Interest

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 5,270,000 shares, a growth of 31.4% from the April 15th total of 4,010,000 shares. Based on an average daily volume of 2,810,000 shares, the days-to-cover ratio is currently 1.9 days.

Insider Activity at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Alexander Mark Schobel sold 50,000 shares of the firm's stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $6.00, for a total transaction of $300,000.00. Following the completion of the transaction, the insider now directly owns 984,476 shares of the company's stock, valued at approximately $5,906,856. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 8.39% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Aquestive Therapeutics during the 1st quarter valued at about $54,000. Jump Financial LLC acquired a new position in shares of Aquestive Therapeutics during the 4th quarter valued at about $60,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Aquestive Therapeutics by 14.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company's stock valued at $379,000 after acquiring an additional 30,898 shares during the last quarter. PFG Investments LLC purchased a new stake in Aquestive Therapeutics in the 1st quarter valued at about $204,000. Finally, Legato Capital Management LLC purchased a new stake in Aquestive Therapeutics in the 4th quarter valued at about $688,000. Institutional investors and hedge funds own 32.45% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on AQST. SVB Leerink began coverage on shares of Aquestive Therapeutics in a research note on Friday. They issued an "outperform" rating and a $8.00 price target on the stock. Piper Sandler began coverage on shares of Aquestive Therapeutics in a research note on Thursday, April 11th. They issued an "overweight" rating and a $10.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research note on Thursday. JMP Securities lifted their price target on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Friday, March 15th. Finally, Raymond James began coverage on shares of Aquestive Therapeutics in a research note on Thursday, March 28th. They issued an "outperform" rating and a $7.00 price target on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $8.00.

Aquestive Therapeutics Trading Up 5.8 %

AQST traded up $0.18 on Monday, hitting $3.27. 1,501,156 shares of the company's stock were exchanged, compared to its average volume of 2,240,448. Aquestive Therapeutics has a fifty-two week low of $1.25 and a fifty-two week high of $6.23. The firm has a 50-day moving average price of $4.21 and a 200-day moving average price of $2.97. The stock has a market cap of $297.70 million, a price-to-earnings ratio of -7.79 and a beta of 2.95.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Tuesday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The business had revenue of $13.21 million for the quarter, compared to the consensus estimate of $11.79 million. On average, equities analysts predict that Aquestive Therapeutics will post -0.4 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.